Deal group includes partners Roger Wallis and Tom Jemson
Chapman Tripp has announced that it assisted EBOS Group Limited with recent equity-raising efforts, consisting of a fully underwritten placement that raised about $217m and an ongoing non-underwritten retail offer that raised $58m.
In a news release, Chapman Tripp said its role in this transaction displayed its “expertise and leadership in advising on high-value capital market transactions.”
The firm’s deal team advised EBOS on the equity raising. The team included:
“EBOS' ability to successfully complete this capital raise during a time of heightened geopolitical volatility is a promising sign and shows the effectiveness of the public equity markets in both New Zealand and Australia,” Wallis said in the firm’s news release.
According to the company’s website, EBOS is an Australasian marketer, wholesaler, and distributor of healthcare, medical, and pharmaceutical products. It also markets and distributes animal care brands.
EBOS has more than 100 locations across New Zealand, Australia, and Southeast Asia, the company’s website noted. EBOS is publicly listed on the stock exchanges of New Zealand and Australia.
In its news release, the law firm shared that the recently raised funds financed EBOS' acquisitions of SVS Veterinary Supplies and the remaining 10-percent stake in Transmedic, a medical technology distributor, while the remaining funds helped finance future growth opportunities.
Chapman Tripp noted that UBS fully underwrote the placement. The firm added that a wide array of current and new investors across New Zealand, Australia, and beyond staunchly supported the placement.
